뉴스필드

노동·인권 전문지

English Edition

Boryung CEO Kim Jung-gyun Secures Majority Stake in Holding Company Through Third-Generation Succession…Boryung Holdings Borrows 70 Billion Won Against 18.4 Million Boryung Shares Just 48 Days After Merger

English translation of the original Korean report. Images and source documents may contain Korean text.

김정균 보령 대표. (사진=보령)
Kim Jung-gyun, CEO of Boryung. (Photo: Boryung)

175 Billion Won from Boryung Biopharma Sale Invested in Capital Increase…Kim Becomes Largest Shareholder, Overtaking His Mother, Chairwoman Kim Eun-sun; 73.1 Billion Won in Holding Company and CEO Loans Due Next June

Kim Jung-gyun, the third-generation owner-family executive and CEO of South Korean pharmaceutical company Boryung (formerly Boryung Pharmaceutical), took a key step in management succession last May by securing a majority stake in the group’s holding company, Boryung Holdings. Boryung Holdings subsequently borrowed 70 billion won by pledging 18.4 million shares of listed company Boryung as collateral just 48 days after the merger.

The pledged shares represent 42.2% of Boryung shares held by Boryung Holdings. Both the holding company’s 70 billion won loan and Kim’s personal loan of 3.1 billion won are due to mature next June.

According to the Financial Supervisory Service’s electronic disclosure system on the 20th, Boryung Holdings pledged 10 million Boryung shares to Shinhan Bank on June 18 and borrowed 30 billion won at an annual interest rate of 4.31%. On the same day, it pledged another 8.4 million shares to Korea Securities Finance Corporation and borrowed 40 billion won at an annual interest rate of 4.53%. The pledged shares represent 21.45% of Boryung’s total issued shares. If current interest rates remain unchanged, annual interest payments will amount to 3.105 billion won.

Kim also personally pledged 694,000 shares, or 84.9% of his directly held 817,583 Boryung shares, to Korea Securities Finance Corporation and borrowed 3.1 billion won at an annual interest rate of 4.37%. Earlier, Boryung Partners, which was controlled by Kim, had also borrowed 30 billion won from KB Kookmin Bank against Boryung shares. However, it repaid the entire amount on April 30, the day before the merger.

Boryung Holdings recorded revenue of 8.974 billion won and an operating loss of 257 million won last year. Of the year-end dividends distributed by Boryung in April this year, Boryung Holdings and Boryung Partners, before their merger, received a combined 6.97311 billion won. Annual interest on the newly borrowed 70 billion won alone amounts to approximately 44.5% of those dividends. However, Boryung Holdings did not disclose the specific purpose for which the borrowed funds would be used.

■ 194.1 Billion Won in Biopharma Sale Proceeds Leads to Majority Control of Holding Company

The shares pledged as collateral this time were accumulated in Boryung Holdings during Kim’s management succession process. Boryung Partners, in which Kim previously held an 88% stake, received 194.1 billion won from selling its stake in vaccine affiliate Boryung Biopharma in 2024. The gain from the share disposal at the time was 179.1 billion won.

Boryung Partners invested 175 billion won of the sale proceeds in Boryung’s paid-in capital increase that same year. By acquiring 18,097,207 newly issued shares through a third-party allotment, it secured a 21.10% stake in Boryung. In effect, funds raised from selling the vaccine affiliate were used to increase its ownership stake in the group’s core listed company.

Kim’s control strengthened further when Boryung Holdings absorbed Boryung Partners in a merger on May 1 this year. Before the merger, Boryung Holdings’ largest shareholder was Kim’s mother, Boryung Chairwoman Kim Eun-sun, with a 44.76% stake, while Kim held 24.01%. However, Kim received newly issued shares through the merger, raising his ownership stake to 51.31% and making him the largest shareholder.

The Boryung shares previously held by Boryung Partners were also transferred to the holding company. As a result, Boryung Holdings’ stake in Boryung increased from 29.71% to 50.80%. This effectively allowed Kim to secure a majority stake in the holding company and control of listed company Boryung without directly receiving his mother’s shares as a gift.

Following this restructuring of the ownership structure, Boryung approved a plan to spin off its prescription drug sales division at an extraordinary general meeting of shareholders held on the 28th of last month. At the time, Boryung Holdings and its specially related parties controlled 67.7% of the voting shares, excluding treasury shares, meaning they alone held enough voting rights to meet the requirements for a special resolution.

Shareholders who opposed the spin-off exercised appraisal rights over 3,253,307 shares, with the total purchase consideration amounting to 29.03251 billion won. Boryung plans to pay that amount on the 15th of next month and complete the spin-off of its prescription drug sales division on January 4 next year.

Approximately five months after the spin-off is completed, Kim’s personal loan of 3.1 billion won and Boryung Holdings’ 70 billion won loan will mature on June 8 and June 18, respectively. The shares pledged as collateral for the holding company’s loan represent 42% of the Boryung shares accumulated in the holding company during the management succession process.

LEAVE A RESPONSE

이메일 주소는 공개되지 않습니다. 필수 필드는 *로 표시됩니다

ESC 또는 배경 클릭하여 닫기